Əsas səhifə

Çap

Əks əlaqə

İnfo
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome

Mündəricat

Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome

Sübutlu məlumatların xülasələri
14.05.2018 • Sonuncu dəyişiklik 14.05.2018
Editors

Letrozole appears to improve live birth and pregnancy rates compared to clomiphene citrate in subfertile women with anovulatory polycystic ovary syndrome, without increasing ovarian hyperstimulation syndrome or miscarriage rates.

The quality of evidence is downgraded by study limitations (unclear allocation concealment in half of the studies and possible selective reporting).

Summary

A Cochrane review included 42 studies with a total of 7935 subjects. Polycystic ovary syndrome (PCOS) is the most common cause of oligomenorrhoea and amenorrhoea. Live birth rates were higher with letrozole (with or without adjuncts) compared to clomiphene citrate (with our without adjuncts) followed by timed intercourse (table ); number needed to treat (NNT) for an additional beneficial outcome 10. Ovarian hyperstimulation syndrome (OHSS) rates and miscarriage rates were similar with letrozole or clomiphene citrate. Live birth rates were similar with letrozole or laparoscopic ovarian drilling, but evidence for a difference in OHSS rates or miscarriage rates was insufficient (table ). There is insufficient evidence for comparison with letrozole vs placebo or letrozole vs selective oestrogen receptor modulators (SERMS).

Letrozole compared to clomiphene citrate for subfertile women with PCOS
OutcomeRelative effect (95% CI) Risk with control- clomifen Risk with intervention - letrozole (95% CI)No of participants (studies) Certainty of evidence
Live birth rate OR 1.68 (1.42 to 1.99)214 per 1000314 per 1000 (279 to 352) 2954 (13) Moderate
OHSSRisk difference (RD) 0.00 (−0.01 to 0.00)5 per 1000 5 per 1000 (5 to 5)2536 (12) High
Clinical pregnancy rate OR 1.56 (1.37 to 1.78)264 per 1000 359 per 1000 (330 to 390)4629 (25) Moderate
Miscarriage rate by pregnancies OR 0.94 (0.70 to 1.26) 201 per 1000 191 per 1000 (150 to 240) 1210 (18) High
Multiple pregnancy rate OR 0.69 (0.41 to 1.16) 17 per 100013 per 1000 (7 to 21) 3579 (17) High
Letrozole compared to laparoscopic ovarian drilling for subfertile women with PCOS
OutcomeRelative effect (95% CI) Risk with control - ovarian drillingRisk with intervention - letrozole (95% CI)No of participants (studies) Certainty of evidence
Live birth rate OR 1.38 (0.95 to 2.02)236 per 1000299 per 1000 (227 to 385) 548 (3) Low
Ovarian hyperstimulation syndrome rate RD 0.00 (−0.01 to 0.01) 0 per 10000 per 1000 (0 to 0) 260 (1) Low
Miscarriage rate by pregnancies OR 0.66 (0.30 to 1.43) 145 per 1000 101 per 1000 (49 to 196)240 (5) Moderate
Multiple pregnancy rate OR 3.00 (0.12 to 74.90) 0 per 10000 per 1000 (0 to 0)548 (3) Low

Clinical comments

Note

Date of latest search:2018-06-14

Ədəbiyyat

  1. Franik S, Eltrop SM, Kremer JA et al. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018;(5):CD010287.